ライフサイエンスコーパス: OVA

1 OVA combines a knowledge-based approach with a variant-f

2 OVA- and house dust mite (HDM)-induced murine asthma mod

3 OVA-induced increases in bronchoalveolar lavage lymphocy

4 OVA-sensitized mice with SD had more severe airway infla

5 OVA-specific CD8(+) T cells transferred to mice immunize

6 On day 14, OVA-specific IgG2a and IgG1 were measured in the serum.

7 In the absence of IL-15, OVA-challenged mice exhibited enhanced bronchial eosinop

8 RNA by means of quantitative PCR, and IL-33, OVA-specific IgE, and mouse mast cell protease 1 by mean

9 In WT mice, PM2.5 + OVA exacerbated OVA-related lung eosinophilia.

10 ive T helper cells are dispensable for acute OVA-induced airway disease but crucial in maintaining ch

11 mation was assessed in mouse models of acute OVA-induced asthma and directed eosinophil migration.

12 OVA + CpG)), an adenovirus encoding OVA (Ad5-OVA), and OVA delivered with incomplete Freund's adjuvan

13 al OVA sensitization and oral or aerosolized OVA challenge, and then they were examined for humoral a

14 Further postnatal aerosolized OVA stress triggered allergic lungs with functional and

15 i.v. 48 h before challenge with aerosolized OVA.

16 After OVA recall, specific IgE concentrations were reduced by

17 hate (S1P) are significantly augmented after OVA treatment in mice.

18 e clinical symptoms in the conjunctiva after OVA challenge were significantly higher in OVA-sensitize

19 early expansion of tissue eosinophils after OVA challenge followed by eosinophil buildup in both com

20 -/-) mice compared with wild-type mice after OVA challenge, consistently with fewer CD4(+) T cells fr

21 tocol (CD4 blockade) and the same target Ag (OVA) achieves Foxp3-dependent transplantation tolerance

22 duction in airway hyperresponsiveness (AHR), OVA allergen-challenged Ormdl3(Delta2-3/Delta2-3)/CC10 m

23 upregulated in conjunctival tissue during an OVA-induced allergic response.

24 inhibiting AHR and airway inflammation in an OVA model of allergic airway inflammation.

25 developed enhanced allergic responses in an OVA-induced model of AAD.

26 imed Ab responses against GFP, ubiquitin, an OVA peptide, and the alpha-helix of influenza hemaggluti

27 VA sensitization prevented food anaphylaxis, OVA-specific IgE production, and intestinal mast cell ex

28 ouse dust mice and Alternaria alternata) and OVA-induced models of active anaphylaxis to determine th

29 e we report that mice with severe asthma and OVA-sensitized/challenged mice had increased PTX3 levels

30 FcRn)-dependent transfer of maternal IgG and OVA immune complexes (IgG-IC) via breast milk and induct

31 in the same period with unadjuvanted OVA and OVA+CAF09 administered via the s.c. or i.m. routes.

32 ), an adenovirus encoding OVA (Ad5-OVA), and OVA delivered with incomplete Freund's adjuvant (IFA(OVA

33 revent the onset of TH2 immune responses and OVA-induced airway hyperresponsiveness or goblet cell hy

34 )CD45RO(+) memory T cells in unimmunized and OVA-immunized BALB/c mice.

35 tress agents may up-regulate unimmunized and OVA-immunized CD4(+)CD44(+) memory T cells by the homeos

36 MWNT-OVA showed limited cellular uptake and OVA specific immune response in contrast to short MWNT-O

37 arge demonstrated better cellular uptake and OVA-specific immune response both in vitro and in vivo.

38 onstrated substantially higher specific anti-OVA IgG antibody levels compared to other transdermal me

39 pendent tolerance when the Ag is provided as OVA-aluminum hydroxide.

40 We addressed this question by assessing OVA-specific immune responses in mice following hepatocy

41 ing the efficacy of a model vaccine in a B16-OVA melanoma mouse model.

42 of infectious tolerance, because IFN-beta + OVA in Alum-specific vaccination inhibited EAE elicited

43 erred into mice bearing established TGF-beta-OVA-expressing thymomas, produce high amounts of IFN-gam

44 s, but occurred at a later step that blocked OVA-specific CD4(+) T cell proliferation and cytokine pr

45 gG immune complexes during pregnancy boosted OVA uptake by fetal dendritic cells (DCs).

46 Both OVA and HDM-induced airway diseases were more severe in

47 lution exceeding 1.0 and CVs of 8.4% for BSA-OVA and 2.4% for OVA-TI, with comparable reproducibility

48 Breastfeeding by OVA-sensitized mothers or maternal supplementation with

49 ecific vaccination inhibited EAE elicited by OVA + MOG in CFA but not EAE elicited by MOG in CFA.

50 s HA-expressing 4T1 mammary carcinoma cells, OVA-expressing EG7 lymphoma cells and CMS5 MCA-induced f

51 n of the IgG response to coimmunized chicken OVA (cOVA), no inhibition was observed when using severa

52 We demonstrated with chicken OVA-specific TCR-transgenic mice that the same tolerizin

53 In contrast, mice receiving CD47-competent OVA(+) hepatocytes showed prolonged and even indefinite

54 ving CD47-deficient, but not CD47-competent, OVA(+) hepatocytes showed significantly enhanced respons

55 Human breast milk containing OVA-IgG-IC induced tolerance in humanized FcRn mice.

56 trasplenic transplantation of CD47-deficient OVA(+) hepatocytes significantly accelerated rejection o

57 plantation from CD47-competent or -deficient OVA-transgenic donors.

58 were immunized with nanoparticles-delivered OVA when compared with free OVA.

59 glycan-structure Lewis(X) (Le(X)) re-directs OVA to the C-type lectin receptor MGL1.

60 8alpha(+) DCs are activated by self-draining OVA+CAF09 in the lymphoid organs, whereas the CD103(+) D

61 vaccine constructs effectively inhibited EG7-OVA tumor growth in mice, however only treatment with th

62 ion of established primary or metastatic EG7.OVA, B16F10, and MC38 tumors; combination with anti-PD-1

63 pG (PLGA(OVA + CpG)), an adenovirus encoding OVA (Ad5-OVA), and OVA delivered with incomplete Freund'

64 nitors attenuated proteolysis of endocytosed OVA for delayed presentation in postnatal life.

65 In WT mice, PM2.5 + OVA exacerbated OVA-related lung eosinophilia.

66 e non-Hodgkin B cell lymphoma that expresses OVA as a model neoantigen.

67 CD4(+)-T cells and cMy-mOVA mice expressing OVA on cardiomyocytes were crossed.

68 o immunization with S. pneumoniae expressing OVA peptide, did not inhibit T cell proliferation in res

69 on of responses to vaccinia virus expressing OVA peptide SIINFEKL by wild-type and Dok-1/2(-/-) CD8(+

70 sing doses of a bronchoconstrictor following OVA immunization and challenge.

71 ificantly reduced within the lungs following OVA or HDM challenge.

72 1.0 and CVs of 8.4% for BSA-OVA and 2.4% for OVA-TI, with comparable reproducibility to glass microde

73 or CTL expressed TCR of varying affinity for OVA.

74 IgA2/IgE ratios for EW and IgA/IgE ratio for OVA were found to be significantly elevated among respon

75 eptor (TSLPR) on CD4 T cells is required for OVA-induced lung inflammation, DCs have also been shown

76 e response than "out" nanoparticles and free OVA.

77 LPS-free OVA does not recapitulate any of the precursor signs of

78 ticles-delivered OVA when compared with free OVA.

79 heir splenocytes were co-cultured with fresh OVA-loaded DCs.

80 tive transfer of splenic CD8(+) T cells from OVA-sensitized WT mice suppressed the enhancement of eos

81 A CD8(+) T cell epitope peptide from OVA (CSIINFEKL) and CpG were co-conjugated to nanopartic

82 Furthermore, OVA-exposed lung Ptx3(-/-) CD4 T cells exhibit an increa

83 Furthermore, treatment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly re

84 vered with incomplete Freund's adjuvant (IFA(OVA)).

85 he AdVCA0848 adjuvant significantly improved OVA-specific T cell responses as detected by IFN-gamma a

86 gamma and IL-2 ELISPOT, while also improving OVA-specific humoral B cell adaptive responses.

87 ry cells and the levels of IL-13 and IL-4 in OVA-challenged airways.

88 IL-6- and IL-23-producing dendritic cells in OVA-exposed Ptx3(-/-) mice compared with those in wild-t

89 IL-13 but suppressed IFN-gamma expression in OVA-specific CD4 Tcon cells.

90 these effects of SEA and IL-13 expression in OVA-specific T cells.

91 r OVA challenge were significantly higher in OVA-sensitized wild-type mice than in control challenged

92 ncreased TH2-mediated airway inflammation in OVA or HDM murine models of asthma.

93 esions and reveal the significance of LPS in OVA used in most studies, thus mimicking natural antigen

94 Furthermore, deletion of MCPIP1 in OVA- or HDM-specific T cells leads to significantly incr

95 e expression and phosphorylation of STAT6 in OVA-exposed mice, whereas Lyn knockdown increased STAT6

96 n, immunization with ovalbumin (OVA) induced OVA-specific B cells only in human IL-6 knock-in mice.

97 To induce allergic airway inflammation, OVA-pulsed DCs from IL-6-deficient or wild-type donors w

98 set of the anaphylactic response to ingested OVA antigen.

99 ce were exposed to a first set of intranasal OVA challenge under SD or healthy sleep (HS) conditions,

100 ated for their resistance to intraperitoneal OVA sensitization and oral or aerosolized OVA challenge,

101 ed by turbidity measurements at different LA/OVA monomer molar ratios (21.5-172) and temperatures (20

102 Studies with fluorescently labelled OVA+CAF09 demonstrated a preferential association of OVA

103 Consequently, Lp/OVA/StII induced a more potent effector function, as sho

104 was encapsulated with OVA into liposomes (Lp/OVA/StII) to assess their efficacy to induce a CTL respo

105 cells transferred to mice immunized with Lp/OVA/StII experienced a greater expansion than when the r

106 ecific CTL response to that observed with Lp/OVA/StII or vesicles encapsulating recombinant StI or th

107 tment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly reduced tumor growth being more n

108 Maternal OVA sensitization prevented food anaphylaxis, OVA-specif

109 emonstrate that CCL7 is required for maximal OVA-induced ocular anaphylaxis, mast cell recruitment in

110 vants that induce distinct cytokine milieus: OVA protein in CFA, aluminum salts (Alum), and Schistoso

111 Accordingly, more OVA-specific IgG1-secreting cells are present in spleen

112 However, long positively-charged MWNT-OVA showed limited cellular uptake and OVA specific immu

113 yielded MWNTs-OVA conjugates were long MWNT-OVA (~386nm), bearing net positive charge (5.8mV), or sh

114 ic immune response in contrast to short MWNT-OVA displaying the least negative charge.

115 VA bearing high negative charges, short MWNT-OVA with the lowest negative charge demonstrated better

116 net positive charge (5.8mV), or short MWNTs-OVA (~122nm) of increasing negative charges (-23.4, -35.

117 Compared to the short MWNTs-OVA bearing high negative charges, short MWNT-OVA with t

118 The yielded MWNTs-OVA conjugates were long MWNT-OVA (~386nm), bearing net

119 While cross-presentation of native OVA requires high antigen dose and TLR stimuli, Le(X) mo

120 No OVA-specific antibodies were induced in response to TAC

121 Presentation of nonsecreted OVA (GFPOVA) by steady-state LCs resulted in transient a

122 Sensitization with OVA plus SEA but not OVA alone induced asthma, and SEA exacerbated asthma ind

123 atment of EAE mice with MOG-psigma1, but not OVA-psigma1, resulted in an influx of IL-10-producing B2

124 MOG-psigma1-, but not OVA-psigma1-induced IL-10-producing Bregs, expressed ele

125 NP-OVA immunization in female but not male CD4-PPARgamma(KO

126 ur previous established murine model of 2-OA-OVA immunization.

127 Administration of OVA+CAF09 via the i.p. route did also result in DC activ

128 We show that a single application of OVA to mouse skin initiates remodeling and cellular infi

129 Application of OVA/IgG immune complexes during pregnancy boosted OVA up

130 9 demonstrated a preferential association of OVA+CAF09 to DCs/monocytes, as compared to macrophages a

131 IgE and IgG1 concentrations in the blood of OVA-sensitized Cyp27b1-KO mice compared with wild-type l

132 Fluorescent conjugates of OVA were used for further studies of mechanisms.

133 tion of uricase inhibited the development of OVA-driven allergic airway disease subsequent to OVA cha

134 ort the hypothesis that the self-drainage of OVA+CAF09 to the draining LNs is required for the activa

135 +) cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous

136 Examination of OVA-challenged IL-15Ralpha(-/-) animals revealed a simil

137 the affinity of the CTL or the expression of OVA in the lymphoma.

138 OVA challenge, as well as the generation of OVA-specific Abs.

139 RSV infection of OVA-sensitized/challenged BALB/c mice resulted in signif

140 ated pTreg were sufficient for inhibition of OVA-induced AHR in an Ag-driven murine model of AAD.

141 demonstrate that PorB increases the level of OVA in the endo-/lysosomal cellular compartment of BMDCs

142 Tumors expressing low levels of OVA could also be eliminated.

143 mphoma cells expressed high or low levels of OVA.

144 In this study, using the mouse model of OVA-induced allergic airway inflammation, we identified

145 erresponsiveness in an experimental model of OVA-induced asthma.

146 Le(X)-modification of OVA favored Th1 skewing of CD4(+) T cells and enhanced c

147 ic Treg or CD4 Tcon cells in the presence of OVA and SEA.

148 oreover, MGL1-mediated cross-presentation of OVA-Le(X) neither required TAP-transporters nor Cathepsi

149 n with OVA and CpG reduces the production of OVA-specific IgE and increases the synthesis of OVA-spec

150 ent) or protein (ovalbumin >90% reduction of OVA present) and organic solvent (ethanol >95% reduction

151 cytes significantly accelerated rejection of OVA(+) skin grafted 7 days after hepatocyte transplantat

152 ons of MDSC on the proliferative response of OVA-specific CD4(+) T cells.

153 or in MC, remarkably mitigates all signs of OVA-mediated remodeling and MC activation.

154 ity of uricase to inhibit the early steps of OVA uptake or processing and presentation by dendritic c

155 ed prolonged and even indefinite survival of OVA(+) skin allografts.

156 with OVA and CpG decreases the synthesis of OVA-specific IgE and skin eosinophil peroxidase activity

157 -specific IgE and increases the synthesis of OVA-specific IgG2a antibodies in an antigen-specific man

158 (OVA) in Was(-/-) mice induced low titers of OVA-specific IgE compared to the WT-OVA/alum model.

159 performed in vivo using adoptive transfer of OVA-specific OT-II cells into wild-type recipients show

160 t repeated intranasal rechallenges with only OVA Ag were sufficient to trigger airway hyperresponsive

161 as a soluble OVA-polysaccharide conjugate or OVA alone.

162 response to OVA-polysaccharide conjugate or OVA.

163 compared with uninfected OVA-treated mice or OVA-treated mice exposed to UV-inactivated RSV.

164 ice were subcutaneously injected with OVA or OVA with PAFR-antagonist WEB2170 on days 0 and 7.

165 these respective APCs from S. pneumoniae- or OVA-immunized mice with OVA-specific T cells, in the abs

166 Oral OVA challenge in sensitized BALB/c mice resulted in a ro

167 e developed allergic diarrhea following oral OVA challenge.

168 Ovalbumin (OVA)-sensitized C57BL/6 mice were exposed to a first set

169 Ovalbumin (OVA)-specific, staphylococcal enterotoxin A (SEA)-nonrea

170 cheally challenged with PM2.5 +/- ovalbumin (OVA) four times at 2-week intervals.

171 juvenile airway disease using an ovalbumin (OVA) allergy model of asthma.

172 cell responses of unimmunized and ovalbumin (OVA)-immunized BALB/c mice, and furthermore, to ascertai

173 Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-type and TLR

174 a surface-adsorbed model antigen [ovalbumin (OVA)] showed that a significantly larger fraction of the

175 und and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1.

176 Development of acute and chronic ovalbumin (OVA)-induced allergic asthma was assessed weekly in CD4(

177 L) simultaneously, 6 h after each ovalbumin (OVA) challenge.

178 We developed CH-NPs encapsulating ovalbumin (OVA) as a model antigen and poly I:C as the adjuvant in

179 Egg white (EW)-, ovalbumin (OVA)-, and ovomucoid (OVM)-specific levels of IgA, IgA1,

180 ceptor (TCR) with specificity for ovalbumin (OVA) on CD4(+)-T cells and cMy-mOVA mice expressing OVA

181 utero injection of adjuvant-free ovalbumin (OVA) was conducted in Gestational Day 14 FVB/N mouse fet

182 ived an irrelevant immunodominant ovalbumin (OVA) peptide, OVA323-339, mice that received MPO409-428

183 Oral administration of ovalbumin (OVA) in Was(-/-) mice induced low titers of OVA-specific

184 y coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyvitamin D3 (

185 We show that the modification of Ovalbumin (OVA) with the glycan-structure Lewis(X) (Le(X)) re-direc

186 l as in vivo in a murine model of ovalbumin (OVA)-induced systemic tolerance.

187 ne the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of

188 e we report that AQP3 potentiates ovalbumin (OVA)-induced murine asthma by mediating both chemokine p

189 nd B cell-deficient mice received ovalbumin (OVA) intranasally before mating.

190 nd activity were evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine models.

191 ivated using dimaprit in both the ovalbumin (OVA) and house dust mite extract (HDM) murine models of

192 proteins (Trypsin Inhibitor (TI); Ovalbumin (OVA); Bovine Serum Albumin (BSA)), we observe resolution

193 C3H/HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated with EPIT us

194 cal properties then conjugated to ovalbumin (OVA), a model antigen.

195 5ac transcript in mice exposed to ovalbumin (OVA).

196 d penetration of a model vaccine, Ovalbumin (OVA), to depths of 500mum into porcine skin.

197 re epicutaneously sensitized with ovalbumin (OVA) and then challenged orally with OVA.

198 ously sensitized female mice with ovalbumin (OVA) followed by epicutaneous sensitization and oral cha

199 ntraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OV

200 In addition, immunization with ovalbumin (OVA) induced OVA-specific B cells only in human IL-6 kno

201 e recipient mice, challenged with ovalbumin (OVA) or house dust mite (HDM), and accessed for TH2 infl

202 applying a skin patch soaked with ovalbumin (OVA) plus CpG, and its suppressor activity was determine

203 re sensitized and challenged with ovalbumin (OVA), and the development of AAD was ascertained by exam

204 Pulmonary immunization with ovalbumin (OVA)-conjugated cationic NPs led to enhanced systemic an

205 sed in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AAI).

206 re sensitized and gavage fed with ovalbumin (OVA).

207 re sensitized and challenged with ovalbumin (OVA).

208 ld-type mice were sensitized with ovalbumin (OVA).

209 r uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like cells in vi

210 ng results: n: 49+/-2 LA molecules bound per OVA monomer unit and Ka: 9.80+/-2.53x10(5)M.

211 ndence of cross-presentation of phagocytosed OVA may principally reflect a requirement for recycling

212 ice or mice diseased from turkey or pheasant OVA-induced DTHR.

213 oparticles, co-loaded with OVA and CpG (PLGA(OVA + CpG)), an adenovirus encoding OVA (Ad5-OVA), and O

214 The ability of PNSN(OVA + CpG) to stimulate cellular and humoral immune resp

215 oadministration of the extracellular protein OVA and the AdVCA0848 adjuvant significantly improved OV

216 eosinophilic inflammation in mice receiving OVA-sensitized splenocytes from AQP3(-/-) mice compared

217 9cRA applied together with repeated OVA challenge transiently increased specific serum IgA,

218 sleep (HS) conditions, followed by a second OVA challenge, 1 week apart.

219 a, intestinal TH2 immune response, and serum OVA-specific IgE and mast cell protease 1 production.

220 lammation, and significantly increased serum OVA-specific IgG1 and IgE in rested mice that previously

221 SHAS-OVA were taken up by human monocyte-derived dendritic ce

222 A released from subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4(+) and CD

223 Allergen-specific immunotherapy with SHAS-OVA as compared to soluble OVA resulted in similar humor

224 sulated with OVA into Lp, elicited a similar OVA-specific CTL response to that observed with Lp/OVA/S

225 reptococcus pneumoniae, as well as a soluble OVA-polysaccharide conjugate or OVA alone.

226 fected by CL injection, internalized soluble OVA.

227 ere not observed with anionic NPs or soluble OVA.

228 therapy with SHAS-OVA as compared to soluble OVA resulted in similar humoral responses but in a highe

229 with 3pRNA protected mice from a subsequent OVA-encoding adenovirus infection in a CD8(+) cell-depen

230 gen-specific IgE responses in mice suffering OVA-induced airway hyperresponsivness (AHR), which was u

231 ed either CD4(+) cells from ROCK2-sufficient OVA TCR transgenic (OT-II) mice or saline i.v. 48 h befo

232 lergic asthmatic inflammation, we found that OVA released from subcutaneously injected SHAS-OVA led t

233 wn and novel disease mutations, we show that OVA performs biologically meaningful candidate variant p

234 The OVA-Le(X)-induced enhancement of T cell cross-priming is

235 The OVA-specific CD4 T cells were then analyzed for IL-13 an

236 The OVA-stimulated cells showed increased expression of seve

237 ereas the CD103(+) DCs are stimulated by the OVA+CAF09 at the SOI.

238 CD4(+) T(Pam3) cells encoding the OVA-specific TCR OT2, when transferred into mice bearing

239 esulted in more severe airway disease in the OVA model, while dimaprit treatment significantly reduce

240 duced in nonobese asthma patients and in the OVA murine model.

241 In the OVA-induced allergic response, the numbers of conjunctiv

242 e whole lung was significantly higher in the OVA-sensitized and -challenged mice which was associated

243 However, surprisingly, import of the OVA peptide SIINFEKL, a CD8(+) T cell epitope frequently

244 Inhibition of the OVA-specific response was not due to the capacity of uri

245 ous autoimmunity despite the fact that their OVA-specific CD4(+)-T cells were not anergic.

246 These OVA-specific antibodies displayed the highest frequency

247 When WEB2170 was added to OVA in complete Freund's adjuvant, enhanced IgG2a but no

248 he respiratory epithelium of mice exposed to OVA or HDM.

249 in unchanged in MC-deficient mice exposed to OVA.

250 promoter region of Muc5ac in mice exposed to OVA.

251 ombination with intranasal (i.n) exposure to OVA.

252 0 T cell binding to DCs and proliferation to OVA peptide.

253 creased vascular permeability in response to OVA challenge after desensitization.

254 inhibit T cell proliferation in response to OVA-polysaccharide conjugate or OVA.

255 /RelA nuclear entry and in vivo responses to OVA peptide.

256 s showed significantly enhanced responses to OVA(+) stimulators compared to sham-operated controls.

257 ce were assessed for clinical sensitivity to OVA, and immunologic parameters were assessed.

258 nockout (KO) mice following sensitization to OVA or intestinal infection with Heligmosomoides polygyr

259 driven allergic airway disease subsequent to OVA challenge, as well as the generation of OVA-specific

260 Foxp3-dependent transplantation tolerance to OVA-expressing skin grafts, but Foxp3-independent tolera

261 Transdermal OVA doses of up to 1mug were achieved in a single 90-sec

262 iferative response of adoptively transferred OVA peptide-specific-transgenic CD4(+) T cells in respon

263 ers of both nontransgenic and TCR-transgenic OVA(257-264)-specific (OT-I) CD8(+) T cells into influen

264 fer of TLR2(-/-) bone marrow into wild-type, OVA-treated C57BL/6 mice blocked rhinovirus-induced airw

265 red within the same period with unadjuvanted OVA and OVA+CAF09 administered via the s.c. or i.m. rout

266 R and eosinophil infiltration, in uninfected OVA-sensitized/challenged mice.

267 ein chemokine [KC]) compared with uninfected OVA-treated mice or OVA-treated mice exposed to UV-inact

268 dults and were highly efficient in taking up OVA/IgG immune complexes.

269 acrophage-like fetal phagocytes that took up OVA and differentiated toward dendritic cells.

270 through the skin and treated with EPIT using OVA-Viaskin patches or oral immunotherapy using OVA.

271 Bone marrow chimera experiments using OVA-treated C57BL/6 and TLR2(-/-) mice were also perform

272 -Viaskin patches or oral immunotherapy using OVA.

273 uld undergo Ag-specific proliferation, using OVA as a model Ag.

274 In this study, using OVA as a model Ag, we assessed the magnitude of the prim

275 By contrast, when OVA was presented by activated LCs, a recallable CTL mem

276 /-) mice were sensitized and challenged with OVA and bronchoalveolar lavage fluid, and the lungs were

277 owever, when these mice were challenged with OVA by gene gun immunization in the contraction phase of

278 r together with SEA and then challenged with OVA or CDE.

279 Mice were orally challenged with OVA to induce anaphylaxis.

280 ory T cells after in vitro coincubation with OVA/IgG-containing AF.

281 chodactyla helianthus, was encapsulated with OVA into liposomes (Lp/OVA/StII) to assess their efficac

282 the StI mutant StI W111C, encapsulated with OVA into Lp, elicited a similar OVA-specific CTL respons

283 skewed responses to postnatal encounter with OVA.

284 suggest that epicutaneous immunization with OVA and CpG decreases the synthesis of OVA-specific IgE

285 Epicutaneous immunization with OVA and CpG reduces the production of OVA-specific IgE a

286 on the immune response by immunization with OVA and induction of chronic graft-versus-host disease i

287 lethal dose of DENV2 and mice immunized with OVA (negative control).

288 Mice were subcutaneously injected with OVA or OVA with PAFR-antagonist WEB2170 on days 0 and 7.

289 )(PLGA)-based microparticles, co-loaded with OVA and CpG (PLGA(OVA + CpG)), an adenovirus encoding OV

290 es approximately 1 mum size were loaded with OVA and the photosensitizer tetraphenyl chlorine disulph

291 ionally, bone marrow-derived DCs loaded with OVA were transferred into naive mice and their splenocyt

292 om S. pneumoniae- or OVA-immunized mice with OVA-specific T cells, in the absence of exogenous Ag, de

293 ons of food allergy in two mouse models with OVA and peanut.

294 n and oral challenge of their offspring with OVA.

295 lbumin (OVA) and then challenged orally with OVA.

296 Sensitization with OVA plus SEA but not OVA alone induced asthma, and SEA e

297 reg cell depletion before sensitization with OVA plus SEA.

298 n, mice were intratracheally sensitized with OVA or cat dander extract (CDE) alone or together with S

299 Vaccination with OVA in combination with 3pRNA protected mice from a subs

300 n adjuvant-based model in wild-type mice (WT-OVA/alum).

301 iters of OVA-specific IgE compared to the WT-OVA/alum model.